| abstract |
The application describes a method for constructing B-lymphocytes using activation-induced cytidine deaminase of B lymphocytes. Thus, the use of engineered nucleases such as Cas nuclease can be avoided. The engineered B cells are useful for the production of individual antibodies and for B cell therapy. Accordingly, the present invention also provides engineered B cells and individual antibodies produced by engineered B cells. |